BioPharma Resources

Drug Trial Radar · NCT03758417

A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

A Phase 2, Open-Label Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA in Chinese Subjects With Relapsed or Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

123

Actual

Start

Jan 23, 2019

Primary completion

Jul 10, 2025

Study completion Oct 20, 2025

Sponsor

Lead sponsor
Nanjing Legend Biotech Co.Industry
Sponsor type
Industry
Collaborators
Janssen Research & Development, LLC
First posted
Nov 29, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of LCAR-B38M chimeric antigen receptor T (CAR-T) cells.

Conditions

  • Multiple Myeloma

Interventions

  • LCAR-B38M CAR-T CellBiological

    Participants will receive LCAR-B38M CAR-T cells as a single infusion which consists of autologous T lymphocytes transduced with LCAR-B38M, a lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR)Time frame: Minimum 2 years after LCAR-B38M chimeric antigen receptor T (CAR-T) infusion (Day 1)

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

  • Fujian Medical University Union hospital

    Fuzhou, Fujian, China

  • Sun Yat -Sen University Cancer Center

    Guandong, Guangzhou, China

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China

  • Shanghai Changzheng Hospital

    Shanghai, Shanghai Municipality, China

  • Ruijin Hospital, Shanghai Jiao Tong University

    Shanghai, Shanghai Municipality, China

  • Shanghai Fourth People Hospital

    Shanghai, Shanghai Municipality, China

  • The Second Affiliated Hospital of Xi'an Jiaotong University

    Xi’an, Shanxi, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

  • The First Affiliated Hospital, Medical School of Zhejiang University

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.